Semaglutide for Women: Wegovy, Ozempic, and What to Know

One Molecule, Two Brand Names

Wegovy and Ozempic both contain semaglutide, a GLP-1 receptor agonist. In casual conversation people swap the names as if they were interchangeable, but the FDA approvals behind them are not the same. Wegovy is approved for chronic weight management. Ozempic is approved for type 2 diabetes. When Ozempic is prescribed specifically to lose weight, that is off-label use of a diabetes drug, not a separate weight product.

For a woman deciding what to ask about, that distinction is practical rather than academic. It shapes what an insurer is being asked to cover, how a clinician frames the plan, and which titration schedule is on the box. Neither brand is a 'stronger' molecule than the other, because it is the same molecule. The difference lives entirely in the label, the approved dose range, and the indication printed on the prescription.

A useful mental model: think of semaglutide as the ingredient and the brand as the container it was approved in. If your goal is weight and you want the on-label route, that is Wegovy. If you have type 2 diabetes, Ozempic is the approved fit and any weight benefit is a welcome side effect of treating the diabetes. You can compare the approved products side by side on our medications hub at /medications before you talk to a prescriber.

How Semaglutide Works in the Body

Semaglutide mimics GLP-1, a hormone your gut releases after eating. Acting on GLP-1 receptors, it prompts the pancreas to release insulin when blood sugar is high, slows how quickly the stomach empties, and signals the brain that you are full. The result most people notice is that appetite quiets down and meals feel satisfying sooner and for longer, which is why the same mechanism helps both blood-sugar control and weight.

That slowed stomach emptying is the thread that connects most of what follows in this guide. It is why nausea is the most common early complaint, why smaller meals feel more comfortable, and, importantly, why a related drug that slows emptying more aggressively carries a birth-control caution that semaglutide does not. Understanding the mechanism makes the brand and safety details below click into place rather than sounding like arbitrary rules.

None of this is instantaneous. Semaglutide is titrated upward slowly over weeks so the body adapts to the gut effects, and the appetite change builds gradually rather than switching on overnight. That deliberate ramp is a feature, not a delay, and it is the reason patience early on tends to pay off in tolerability later.

What the Weight-Loss Evidence Shows

The pivotal obesity trial for semaglutide, known as STEP 1, was published in the New England Journal of Medicine in 2021 and ran for 68 weeks in adults with overweight or obesity. It is the study underpinning the weight-management approval, and its participant population skewed female, so a large share of the core evidence reflects outcomes in women rather than being extrapolated from a mostly-male sample.

We deliberately do not headline a single weight-loss percentage on this page, because individual results vary widely and the number that circulates online is usually stripped of its trial context. What the evidence supports is qualitative and still useful: over a long, controlled study, semaglutide produced meaningful, sustained weight reduction alongside lifestyle changes. That is a stronger foundation than most over-the-counter approaches can claim.

Semaglutide has also been studied head-to-head against the dual agonist tirzepatide in people with type 2 diabetes, in a trial called SURPASS-2. It is the one true head-to-head between these molecules, and it is worth knowing that comparison exists rather than relying on cross-trial guesses. Broader network meta-analyses that rank obesity drugs indirectly, such as one published in the BMJ in 2026, exist too, but indirect comparisons are weaker evidence than a direct trial and should be read with that caveat in mind.

Wegovy vs Ozempic: The Approval That Changes Everything

The single most consequential fact about these two brands is what each is approved to treat. That approval determines whether your use is on-label or off-label, which in turn ripples into coverage decisions and how a prescriber documents the plan. The table below lays out the differences that actually affect a woman's decision, using only what the labels establish.

Notice that the injection format and the molecule are identical; both are once-weekly subcutaneous shots of semaglutide. What differs is the indication and the dose the medication is titrated toward. Reading a row at a time is the fastest way to see why 'Wegovy or Ozempic?' is really a question about which approved reason applies to you.

Why the Off-Label Distinction Matters for Women

Off-label prescribing is legal and common, and it does not mean a use is unsafe. It means the drug is being prescribed outside the specific indication the FDA reviewed. When Ozempic is used for weight, the practical consequences show up in coverage and access rather than in the pharmacology, since the molecule is the same one inside Wegovy.

This matters more for women in a few recurring situations. If weight is entangled with PCOS or midlife metabolic change, a clinician may reach for whichever product is available and affordable, which can mean the diabetes brand used off-label. Knowing that framing helps you ask the right questions: is this on-label or off-label for me, what does that mean for refills, and is the on-label alternative an option worth pursuing.

Supply has also been uneven across the GLP-1 category, and shortages can push people toward whatever they can get rather than the ideal fit. That is a reason to plan with a prescriber rather than improvise, and a reason to be cautious about sources outside the normal pharmacy channel, which we cover in the access section below.

The Contraception Rule That Does NOT Apply to Semaglutide

This is the single most-confused point online, so read it carefully. Tirzepatide, the molecule in Zepbound and Mounjaro, carries a specific label warning: because it slows gastric emptying, it can reduce the absorption and effectiveness of oral hormonal birth control, and the label advises adding a barrier method or switching to a non-oral contraceptive around starting the drug and around each dose increase. That warning is real, and it belongs to tirzepatide.

Semaglutide, meaning both Wegovy and Ozempic, does not carry that oral-contraceptive interaction warning. If you have read that 'GLP-1 drugs cancel out your birth control pill,' that statement is being lifted from the tirzepatide label and misapplied to semaglutide. Do not assume the tirzepatide rule applies here. It does not mean contraception is irrelevant on semaglutide, only that the particular pill-effectiveness caution attached to tirzepatide is not part of semaglutide's labeling.

The table below makes the difference concrete, because the two drugs are easy to blur together when both are marketed for weight and diabetes under paired brand names.

Pregnancy: Why Semaglutide Is Stopped Before Conceiving

Semaglutide is not for use during pregnancy. The consistent guidance across GLP-1 medications is that they should be stopped when pregnancy is planned or confirmed, because deliberate weight loss is never a goal during pregnancy and the drug's safety in pregnancy is not established. If you are trying to conceive, this is a conversation to have with your clinician about stopping the medication well ahead of time rather than at the moment of a positive test.

The Wegovy labeling addresses pregnancy directly, and the takeaway for planning is simple: build the timing into your decision from the start. If pregnancy is on your horizon in the near term, that is relevant to whether now is the right window to begin, and to how far in advance you would plan to stop.

This is one of the places where a woman's situation genuinely changes the calculus, and it deserves an explicit discussion rather than an assumption. A prescriber can help you map the stop-and-restart timing around your own family plans.

Fertility and Restored Ovulation

There is a second reason contraception matters even though semaglutide lacks the tirzepatide pill warning. Weight loss itself can restore ovulation in people who were not ovulating regularly, which means fertility can return quietly and sometimes unexpectedly as weight comes down. Anyone who could become pregnant and does not intend to should still use effective contraception while on the drug.

The point here is worth stating precisely because it is so often garbled. The reason to keep using contraception is not a pill-interaction rule, which is tirzepatide's, but the simple fact that becoming more fertile can happen without warning. Those are two different mechanisms, and only the second one applies to semaglutide.

For women with PCOS in particular, this cuts both ways: restored ovulation can be welcome if pregnancy is the goal, or a reason for reliable contraception if it is not. Either way, it belongs in the plan rather than being discovered after the fact.

PCOS and Off-Label Use

Polycystic ovary syndrome comes up constantly in the same breath as GLP-1 drugs, because PCOS often involves insulin resistance and weight that is stubborn to shift. It is important to be precise: PCOS is not an FDA-approved indication for semaglutide. Any use of Wegovy or Ozempic for PCOS is off-label, meaning a clinician is prescribing outside the approved label based on clinical judgment.

The 2023 international evidence-based PCOS guideline supports active metabolic management and recognizes a role for the broader metabolic picture, but it still places lifestyle measures and metformin as first-line. So the accurate framing is that semaglutide may be discussed as an off-label option after first-line steps, not as an approved PCOS treatment. That is a discussion for your own clinician, informed by your labs and history, not a decision to make from a web page.

If PCOS is your reason for reading this, our PCOS category at /categories/pcos gathers the approved and off-label context in one place so you can go into that appointment with the right questions rather than marketing claims.

Menopause, Midlife Weight, and Body Composition

Weight in the menopause transition is not just a matter of willpower, and it helps to say so plainly. Research on body composition through the midlife transition, including work published in JCI Insight in 2019, documents shifts in fat and lean mass that are part of the biology of this stage, not a personal failing. That context matters because many women arrive at the GLP-1 conversation after years of being told to simply try harder.

Semaglutide is a weight and diabetes drug, not a menopause treatment, and it does not replace care for menopausal symptoms. The genitourinary and hormonal aspects of menopause are managed on their own track, as reflected in menopause society position statements, and those are separate conversations from weight management. Conflating the two leads to disappointment on both fronts.

If you are trying to figure out where menopause-related weight fits against hormonal symptom care, our menopause matcher at /tools/menopause-matcher can help you sort which questions belong to which clinician, so semaglutide is considered for what it actually treats rather than as a catch-all.

Side Effects Women Should Plan For

The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, and a general sense of fullness. They tend to be worst early and around each dose increase, which is exactly why the drug is titrated slowly. For most people the gut settles as the body adapts, and smaller, lower-fat meals make the adjustment easier.

There are effects the label takes more seriously, including gallbladder problems, pancreatitis, and a boxed thyroid tumor consideration tied to the drug class, which is why personal and family medical history belongs in the prescribing conversation. This guide cannot substitute for that individualized review, and none of it should be read as a reason to self-start or self-adjust the medication.

For women specifically, a few practical threads deserve attention: appetite suppression can make it harder to eat enough protein and nutrients, restored fertility can change contraception needs as covered above, and any plan around pregnancy timing interacts with the drug. Building those into the plan up front tends to make the experience smoother than discovering them later.

Access: Insurance, Compounded, and Unapproved Products

High demand has produced a market for compounded and unapproved 'semaglutide' products sold outside the normal pharmacy channel. The FDA has publicly flagged concerns about unapproved GLP-1 drugs used for weight loss, including dosing errors and products that are not what they claim to be. For a woman comparing options, the safer default is the FDA-approved branded product prescribed and monitored by a clinician.

If cost or access is pushing you toward an unapproved source, treat that as a signal to talk to a clinician about legitimate routes rather than a reason to buy something unverified. Coverage often hinges on the on-label versus off-label distinction discussed earlier, so understanding which brand and which indication apply to you is part of solving the access problem, not separate from it.

Our brand directory at /brands and medications hub at /medications focus on the approved products and how they are actually used, so you are comparing like with like rather than against a gray-market unknown of uncertain contents.

How to Decide With Your Clinician

Pulling the threads together, the semaglutide decision for a woman is less about the molecule and more about your specific situation mapped onto the approved options. The core questions are answerable: is my use on-label Wegovy or off-label Ozempic, does pregnancy timing change my window, does PCOS or menopause context change the framing, and am I clear that the tirzepatide birth-control rule does not apply here.

Bring those questions to a prescriber rather than trying to settle them alone. A clinician can weigh your history against the side-effect profile, help you plan contraception and any pregnancy timing, and steer you toward approved products rather than unverified ones. That is the version of this decision that respects both the evidence and your individual biology.

Use this guide to arrive informed, not to self-prescribe. The strongest outcome comes from a shared decision built on accurate facts, which is exactly what the sections above are meant to give you.

Questions to ask your clinician

Bring these to your appointment — they turn a vague visit into a decision.

• Should I be on Wegovy (on-label for weight) or is Ozempic being prescribed off-label for me, and what does that mean for my coverage and refills?
• Given my family plans, when would I need to stop semaglutide before trying to conceive, and how would we time restarting it?
• I could become pregnant and do not intend to right now — what contraception do you recommend, knowing weight loss can restore ovulation?
• With my PCOS, where does semaglutide fit relative to lifestyle changes and metformin, and is off-label use appropriate for me yet?
• Do my personal and family medical history raise any flags for the thyroid, gallbladder, or pancreatitis cautions on the label?
• How should I plan meals to get enough protein and nutrients while my appetite is suppressed?
• Is my weight tied to the menopause transition, and should any menopausal symptoms be managed separately from this medication?

Frequently asked questions

Are Wegovy and Ozempic the same thing?

They contain the same active drug, semaglutide, but they are approved for different uses. Wegovy is approved for chronic weight management; Ozempic is approved for type 2 diabetes, and using it for weight loss is off-label. Same molecule, different labels and target doses.

Does semaglutide make birth control pills less effective?

No. Semaglutide (Wegovy and Ozempic) does not carry the oral-contraceptive interaction warning. That specific warning applies to tirzepatide (Zepbound and Mounjaro), which advises a barrier method or a non-oral contraceptive around starting and each dose increase. It is frequently and incorrectly attributed to semaglutide.

Can I take semaglutide while pregnant or trying to conceive?

No. Semaglutide is not for use in pregnancy and should be stopped when pregnancy is planned or confirmed, because weight loss is not a pregnancy goal. Discuss timing with your clinician, and note that weight loss can restore ovulation, so contraception still matters if you could conceive and do not intend to.

Is semaglutide approved for PCOS?

No, PCOS is not an FDA-approved indication for semaglutide, so any such use is off-label. The 2023 international PCOS guideline still lists lifestyle changes and metformin as first-line; GLP-1-type therapy sits in the broader metabolic picture, not as an approved PCOS treatment.

Were women included in the semaglutide trials?

Yes. In STEP 1, the pivotal 68-week semaglutide obesity trial published in NEJM in 2021, women were the majority of participants, so the core weight-management evidence reflects women's outcomes rather than being extrapolated from a mostly-male study.

How is semaglutide different from tirzepatide?

Semaglutide is a GLP-1 receptor agonist; tirzepatide is a dual GLP-1/GIP agonist. Semaglutide is sold as Wegovy (weight) and Ozempic (diabetes); tirzepatide is sold as Zepbound (weight) and Mounjaro (diabetes). One practical difference for women: tirzepatide labels carry an oral-contraceptive warning that semaglutide does not.

Have the two drugs been compared directly?

Yes, in people with type 2 diabetes. SURPASS-2 is the one true head-to-head trial comparing semaglutide and tirzepatide. Broader rankings from indirect network meta-analyses exist too, but indirect comparisons are weaker evidence than a direct trial.

How does semaglutide actually cause weight loss?

It mimics the gut hormone GLP-1, prompting insulin release when blood sugar is high, slowing stomach emptying, and signaling fullness to the brain. Appetite quiets and meals feel satisfying sooner, which drives both weight loss and better blood-sugar control. The effect builds gradually as the dose is titrated up.

What are the most common side effects?

Gastrointestinal effects are most common: nausea, vomiting, diarrhea, constipation, and fullness, usually worst early and around dose increases. The label also flags more serious considerations including gallbladder issues, pancreatitis, and a class-wide thyroid tumor caution, which is why your medical history belongs in the prescribing conversation.

Is compounded semaglutide safe?

Approved, pharmacy-dispensed products are the safe baseline. The FDA has warned about unapproved GLP-1 products sold for weight loss, including dosing errors and products that are not what they claim. If cost is pushing you toward an unapproved source, use that as a reason to ask a clinician about legitimate options.

Does semaglutide help with menopause weight gain?

It is a weight and diabetes drug, not a menopause treatment. Body composition genuinely shifts through the menopause transition, so weight in midlife is not simply a willpower issue, but menopausal symptoms are managed on a separate track. Semaglutide should be considered for what it treats, not as a catch-all for menopause care.

Will I need contraception even without the tirzepatide warning?

Yes, if you could become pregnant and do not intend to. The reason is not a pill-interaction rule, which belongs to tirzepatide, but that weight loss can restore ovulation and return fertility unexpectedly. That is a different mechanism, and it still means reliable contraception matters on semaglutide.

Primary sources

1. STEP 1: Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021 (pivotal 68-week semaglutide obesity trial; majority-female participants).
2. SURPASS-2: Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes. NEJM 2021 (the only direct head-to-head between the two molecules).
3. FDA label: Wegovy (semaglutide) — approved for chronic weight management; pregnancy guidance.
4. FDA label: Zepbound (tirzepatide) — oral-contraceptive interaction warning and pregnancy guidance (applies to tirzepatide, not semaglutide).
5. FDA label: Mounjaro (tirzepatide) — oral-contraceptive interaction warning (tirzepatide only).
6. 2023 International Evidence-based Guideline for the Assessment and Management of PCOS. Human Reproduction 2023 (lifestyle + metformin first-line; metabolic management context).
7. Body composition changes across the menopause transition. JCI Insight 2019.
8. Obesity drugs network meta-analysis (indirect comparisons). BMJ 2026.
9. FDA: Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.